Benzinga Finance on MSN12d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Mainz Biomed N.V. ( NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in ...
Mainz Biomed's collaboration with Thermo Fisher aims to advance mRNA-based colorectal cancer screening technologies. ColoAlert improvements reduce retesting rates, delivering results in 2–3 days ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...
In einem turbulenten Marktumfeld hat die Aktie von Mainz Biomed (NASDAQ: MYNZ) BV ein 52-Wochen-Tief erreicht und ist auf 6,12 US-Dollar gesunken. Das für innovative Krebsscreening-Technologien bekann ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback